202 related articles for article (PubMed ID: 10090425)
1. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.
Lode H; Vogel F; Elies W
Clin Ther; 1999 Jan; 21(1):61-74; discussion 1-2. PubMed ID: 10090425
[TBL] [Abstract][Full Text] [Related]
2. The safety profile of the fluoroquinolones.
Bertino J; Fish D
Clin Ther; 2000 Jul; 22(7):798-817; discussion 797. PubMed ID: 10945507
[TBL] [Abstract][Full Text] [Related]
3. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context.
Ball P; Mandell L; Patou G; Dankner W; Tillotson G
Int J Antimicrob Agents; 2004 May; 23(5):421-9. PubMed ID: 15120718
[TBL] [Abstract][Full Text] [Related]
4. Safety profile of grepafloxacin compared with other fluoroquinolones.
Stahlmann R; Schwabe R
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():83-92. PubMed ID: 9484877
[TBL] [Abstract][Full Text] [Related]
5. Safety profile of sparfloxacin, a new fluoroquinolone antibiotic.
Lipsky BA; Dorr MB; Magner DJ; Talbot GH
Clin Ther; 1999 Jan; 21(1):148-59. PubMed ID: 10090432
[TBL] [Abstract][Full Text] [Related]
6. Prulifloxacin: a new antibacterial fluoroquinolone.
Prats G; Rossi V; Salvatori E; Mirelis B
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):27-41. PubMed ID: 16441207
[TBL] [Abstract][Full Text] [Related]
7. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial safety: focus on fluoroquinolones.
Owens RC; Ambrose PG
Clin Infect Dis; 2005 Jul; 41 Suppl 2():S144-57. PubMed ID: 15942881
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis.
DeAbate CA; Bettis R; Munk ZM; Fleming H; Munn NJ; Riffer E; Bagby B; Giguere G; Collins JJ
Clin Ther; 1999 Jan; 21(1):172-88. PubMed ID: 10090434
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily.
Chodosh S; Lakshminarayan S; Swarz H; Breisch S
Antimicrob Agents Chemother; 1998 Jan; 42(1):114-20. PubMed ID: 9449270
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of linezolid in children.
Saiman L; Goldfarb J; Kaplan SA; Wible K; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S193-200. PubMed ID: 14520146
[TBL] [Abstract][Full Text] [Related]
12. A review of the safety profile of cefixime.
Wu DH
Clin Ther; 1993; 15(6):1108-19. PubMed ID: 8111808
[TBL] [Abstract][Full Text] [Related]
13. The clinical tolerability profile of alendronate.
Watts N; Freedholm D; Daifotis A
Int J Clin Pract Suppl; 1999 Apr; 101():51-61. PubMed ID: 12669741
[TBL] [Abstract][Full Text] [Related]
14. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance.
Voth M; Rosenberg M; Breuer J
Invest Radiol; 2011 Nov; 46(11):663-71. PubMed ID: 21623211
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia.
Topkis S; Swarz H; Breisch SA; Maroli AN
Clin Ther; 1997; 19(5):975-88. PubMed ID: 9385485
[TBL] [Abstract][Full Text] [Related]
16. Grepafloxacin.
Wagstaff AJ; Balfour JA
Drugs; 1997 May; 53(5):817-24; discussion 825-7. PubMed ID: 9129868
[TBL] [Abstract][Full Text] [Related]
17. A critical review of the fluoroquinolones: focus on respiratory infections.
Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
[TBL] [Abstract][Full Text] [Related]
18. Safety profile of cefditoren. A pooled analysis of data from clinical trials in community-acquired respiratory tract infections.
Granizo JJ; Aguilar L; Gimenez MJ; Coronel P; Gimeno M; Prieto J
Rev Esp Quimioter; 2009 Jun; 22(2):57-61. PubMed ID: 19544097
[TBL] [Abstract][Full Text] [Related]
19. Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
Talan DA
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S64-71. PubMed ID: 11249831
[TBL] [Abstract][Full Text] [Related]
20. Fluoroquinolone toxicity profiles: a review focusing on newer agents.
Lipsky BA; Baker CA
Clin Infect Dis; 1999 Feb; 28(2):352-64. PubMed ID: 10064255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
